Description
Calvenza™ EIV is Equine Influenza Killed Virus Vaccine.

Features
•Efficacy based on challenge studies for EIV.
•Incorporates North American (Kentucky/95) & Eurasian (Newmarket/2/93) EIV A2 strains and an EIV A1 strain.
•Novel adjuvant.
•Safe, all killed vaccine.
•Includes innovative pliable nasal applicator.

Benefits
•Flexible dose administration.
•Three dose regimen conforms to AAEP recommendations.
•No reversion to virulence.
•Minimal vaccine site reactions.

Advantages
•Calvenza™ EIV is proven safe.
•Calvenza™ EIV is proven effective by challenge.

Dosage & Administration
Using aseptic technique inoculate horses IM with a 2 mL dose. Administer a second 2 mL dose IM in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks IM or IN. Revaccinate annually and prior to anticipated exposure IM or IN.

Precautions
Store at a temperature between 35° - 45° F (2° - 7° C). Protect from freezing. Shake well before using. Do not vaccinate within 21 days of slaughter. Antidote: Epinephrine.

Uses
For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory disease due to equine influenza types A1 and A2 viruses.

Warning
This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Highlights
•First killed virus vaccine with relevant North American & Eurasian EIV A2 strains approved in the United States.
•Efficacy demonstrated by challenge studies.
•Flexible routes of administration.
•Proven safe with minimal vaccine site reaction.
•Safe for use in pregnant mares.